key: cord-0717135-hh7rxurl
authors: Han, Lefei; Zhao, Shi; Cao, Wangnan; Javanbakht, Mohammad; Ran, Jinjun; Sun, Shenzhi
title: Changes in renal failure mortality during the COVID-19 pandemic in the United States
date: 2021-08-21
journal: J Nephrol
DOI: 10.1007/s40620-021-01145-4
sha: a0d75aaaf4caf897ca2db5e6250061360eb553ce
doc_id: 717135
cord_uid: hh7rxurl

[Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-021-01145-4.

failure were identified based on the International Statistical Classification of Diseases Tenth Revision and were coded from N17 to N19. To evaluate the indirect impacts on renal failure mortality, we excluded deaths from COVID-19.

We divided 2020 into the pre-pandemic phase (January 1 to March 17), early pandemic phase (March 18 to June 2), and later pandemic phase (June 3 to August 18). We defined the start date (March 18, 2020) of the pandemic according to the rapid increase in COVID-19 cases and the implementation of the 'stay-at-home' order in the US [1] . A total of 33 jurisdictions were included after excluding jurisdictions with missing data.

We used an analogue of the 'difference-in-difference' comparison approach to examine the changing rates in renal failure deaths during the pandemic [1] . We used the Poisson regression model separately for each jurisdiction to compare the relative change in the death rates during the pandemic phase versus the pre-pandemic phase in 2020. We also used the same approach to compare the death rates in the analogous period in 2015-2019. We then calculated the ratio of the relative change in death rates in 2020 versus the relative change in death rates in 2015-2019. This approach allows us to estimate the increase in renal failure deaths associated with the pandemic while controlling for long-term trends and seasonal variations in renal failure deaths and variables that do not change markedly with time, such as age, sex, and race. All analyses were conducted by R 3.6.1. From January 1 to August 18, 2020, there were 33,775 renal failure deaths in the US, approximately a 3.3% increase compared to the historical level. Texas (9.8%), California (9.2%), and Florida (6.9%) were the three most affected jurisdictions. Compared with the baseline death rate in 2015−2019, we observed two increases in renal failure death rates in 2020: one in April and the other one from July to August (Supplementary Figure) .

Nationally, the pandemic period was associated with an increased mortality rate of renal failure (Table 1) . Texas, Missouri, and New Jersey showed marginal rises in the ratio of the relative change in renal failure deaths. Compared with the early pandemic phase, the ratio of relative change in death rates was slightly increased in the later pandemic phase (Supplementary Table) . Only Texas and New Jersey showed apparent mortality increases in both early and later pandemic phases.

Several reasons might explain the increased death rates in renal failure during the pandemic. First, given the rising concerns on the nosocomial transmission of COVID-19, some patients may have avoided visiting hospitals for necessary treatments, and some healthcare providers might have decided to postpone scheduled services. This delayed treatment of renal failure could have resulted in excess deaths. Second, part of nephrology care had to be delivered by telehealth services during the pandemic. Patients may have failed to receive quality care if they had difficulty accessing telemedical services, especially older people or those from rural areas. Third, nephrology healthcare providers encountered a dramatic challenge in balancing their routine workload and their surging workload with COVID-19 patients with kidney involvement during hospitalization, telemedical nephrology services and self-protection for COVID-19. The challenges were likely also shared with specialties of other diseases, such as cardiovascular disease and diabetes [1, 2] . Finally, overwhelming medical sources possibly occurred because of insufficient medical replenishment and excess consumption for COVID-19 patients with kidney function exacerbation, which might also have led to increased renal failure mortality [5] .

Limitations of this study include the possibility of incomplete reporting of deaths and inability to generalize study findings to jurisdictions with missing data.

In conclusion, we identified increased mortality rates of renal failure during the COVID-19 pandemic in the US. Our findings highlight the importance of timely management and quality care for patients with chronic renal illness during the COVID-19 period.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s40620-021-01145-4.

Author contributions L.H. contributed to data analysis and wrote the manuscript. S.Z. and J.R. researched data and contributed to data analysis. W.C. contributed to discussion and reviewed/edited the manuscript. M.J. contributed to discussion. S.S. designed the study and reviewed/edited the manuscript. J.R. designed the study and contributed to discussion. All authors gave final approval for publication.

The study was funded by SJTU Scientific Research Initiative, No. 21X010501093.

Ethical approval The study adhered to the Declaration of Helsinki. As the data were publicly available and data were aggregated and de-identifiable, institutional review board approval and informed consent were not needed.

Consent to participate Not applicable.

Cardiovascular Deaths During the COVID-19 Pandemic in the United States

Increase in diabetes mortality associated with COVID-19 pandemic in the

The COVID-19 Pandemic Converges With Kidney Policy Transformation: Implications for CKD Population Health

Weekly counts of death by jurisdiction and cause of death 2020

Ethics of kidney care in the era of COVID-19

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations